Welcome to our dedicated page for ARCELLX SEC filings (Ticker: ACLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Arcellx, Inc. (NASDAQ: ACLX), a clinical-stage biotechnology company developing cell therapies and immunotherapies for cancer and other incurable diseases. Through these filings, investors can review how Arcellx reports its financial condition, collaboration revenue, research and development spending, and progress toward potential commercialization.
Arcellx uses periodic and current reports to disclose key information. For example, the company files Form 8-K to furnish press releases announcing quarterly financial results, as reflected in 8-K filings tied to results for quarters ended June 30 and September 30, 2025. These filings describe collaboration revenue associated with its partnership activities, research and development expenses related to clinical and preclinical programs, general and administrative expenses, and net losses as the company advances its pipeline.
In addition to 8-Ks, investors can use this page to find Arcellx’s annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These documents typically provide detailed discussions of the company’s lead BCMA-directed CAR T-cell therapy, anitocabtagene autoleucel (anito-cel), its Phase 2 iMMagine-1 and Phase 3 iMMagine-3 studies in relapsed or refractory multiple myeloma, regulatory designations, and its global strategic collaboration with Kite, a Gilead Company.
Stock Titan enhances these filings with AI-powered summaries that highlight key points such as revenue trends, R&D and G&A dynamics, cash runway disclosures, and material clinical or regulatory updates. Users can also review insider transaction reports on Form 4, proxy statements on Form DEF 14A, and other relevant submissions as they appear in the SEC’s EDGAR system. Together, these resources help investors and researchers quickly interpret Arcellx’s regulatory disclosures and understand the financial and operational context behind ACLX.
New Enterprise Associates and related managers report that they no longer beneficially own any Arcellx (ACLX) common stock. This Schedule 13D/A Amendment No. 6 follows Gilead’s acquisition of Arcellx, completed via a tender offer and merger on April 28, 2026.
Under the merger terms, Gilead’s subsidiary purchased all outstanding Arcellx shares for $115.00 in cash per share, plus one contractual contingent value right per share, which may pay an additional $5.00 in cash upon achieving a specified milestone. After tendering all of their shares into the offer, the reporting funds’ beneficial ownership fell to 0.00 shares, or 0% of Arcellx’s outstanding common stock.
Arcellx, Inc. director Jill Carroll reported dispositions tied to the company’s acquisition by Gilead Sciences. A fund associated with her, SR One Capital Fund I Aggregator, LP, tendered 1,479,148 shares of Arcellx common stock in a cash tender offer. According to the merger agreement, each tendered share was exchanged for $115.00 in cash plus one contingent value right that may pay $5.00 in cash under specified conditions. Carroll is a partner at affiliated SR One entities and disclaims beneficial ownership of these securities except for any pecuniary interest.
The filing also shows that three Arcellx stock option awards, covering 9,174, 8,011 and 11,459 shares at exercise prices of $63.68, $51.30 and $37.94, were disposed of to the issuer when the merger closed. Under the merger terms, each qualifying option was canceled and converted into a cash payment equal to the spread above $115.00 per share, plus one contingent value right for each underlying share. After these transactions, no Arcellx common stock or options are reported as held by Carroll or the related fund.
Arcellx, Inc. director Ali Behbahani and related holdings reported dispositions tied to the company’s merger with Gilead Sciences. Common shares tendered into the offer were exchanged for $115.00 in cash per share plus one contingent value right for an additional $5.00 in cash, subject to conditions. The filing also shows all reported stock options were canceled and converted into cash payments based on the difference between the $115.00 closing amount and each option’s exercise price, plus contingent value rights. Following these tender-offer and issuer dispositions, the filing reports zero Arcellx common shares and options remaining for the reporting person.
Arcellx, Inc. director Olivia C. Ware reported the disposition to the issuer of four stock option grants totaling 65,450 options on Common Stock. The options had exercise prices of $63.68, $51.30, $37.94, and $7.61 per share and now show zero options remaining for each grant.
According to the merger agreement among Arcellx, Gilead Sciences, Inc., and Ravens Sub, Inc., these Company Options, each with a per share exercise price below the $115 Closing Amount, were canceled and converted into cash and contingent rights. For each option share, the holder became entitled to a lump-sum cash payment equal to $115 minus the applicable per share exercise price, multiplied by the number of shares, plus one contractual contingent value right per underlying share.
Arcellx, Inc. director Kavita Patel reported the cancellation of multiple stock option awards in connection with Arcellx’s merger with Gilead Sciences. On April 28, 2026, five blocks of stock options covering Arcellx common stock were disposed of in transactions classified as dispositions to the issuer.
The options covered 9,174 shares at an exercise price of $63.68 per share, 8,011 shares at $51.30, 11,459 shares at $37.94, 20,513 shares at $15.00, and 27,077 shares at $6.66. Each block shows zero derivative shares remaining after the transactions.
According to the merger agreement among Arcellx, Gilead Sciences, and a Gilead subsidiary, each outstanding company stock option with a per share exercise price below a Closing Amount of $115 per share was canceled and converted into the right to receive a lump-sum cash payment and one contractual contingent value right for each share subject to the option.
Arcellx, Inc. director Kristin Myers reported the disposition of stock options to the company in connection with a completed merger with a subsidiary of Gilead Sciences, Inc. Each option covered Arcellx common stock.
On the transaction date, 1,784 options with a per share exercise price of $63.68 and 16,829 options with a per share exercise price of $69.87 were canceled and surrendered to the issuer. Following these transactions, no options from these grants remained outstanding.
Under the merger agreement, each canceled company option with an exercise price below the $115 "Closing Amount" was converted into the right to receive a lump-sum cash payment based on the spread between $115 and the option’s exercise price, multiplied by the shares subject to the option, plus one contractual contingent value right for each underlying share.
Lubner David Charles reported disposition transactions in this Form 4 filing.
Arcellx director David Charles Lubner exited his position as part of the Gilead acquisition. He tendered 21,659 shares of Arcellx common stock into Gilead’s offer, receiving $115.00 per share in cash plus one contingent value right (CVR) promising a potential $5.00 cash payment per CVR.
In addition, all his outstanding stock options with exercise prices below $115.00 were canceled and converted into cash equal to the spread between $115.00 and each option’s exercise price, plus one CVR for each underlying share. Following these tender offer and option cancellation transactions, Lubner reported holding no Arcellx securities.
Arcellx director Andrew H. Galligan reported dispositions tied to the company’s merger with Gilead Sciences. A trust associated with him tendered 5,000 shares of Arcellx common stock in the offer, receiving $115.00 per share in cash plus a contractual contingent value right for an additional $5.00 per share, subject to conditions.
In addition, two blocks of Arcellx stock options were canceled and converted under the merger terms: 1,784 options with a $63.68 exercise price and 16,829 options with a $69.87 exercise price. These were exchanged for cash equal to their in-the-money value and one contingent value right per underlying share, leaving no reported remaining holdings in this filing.
Arcellx, Inc. chief financial officer Michelle Gilson reported merger‑related transactions in Arcellx (ACLX) stock and equity awards tied to the company’s acquisition by Gilead Sciences. Common shares, including 5,000 held by a family charitable foundation and 67,048 held directly, were disposed of in a tender offer and exchanged for $115.00 per share in cash plus a contingent value right (CVR) for a possible additional $5.00 per share equivalent, subject to tax withholding.
In connection with the same merger, multiple equity awards were canceled and converted into cash and CVRs, including performance‑based and time‑based restricted stock units and stock options with exercise prices of $56.15, $31.03, $19.97, and $8.66 per share. The filing also reports a grant of 59,028 performance‑based restricted stock units, each representing a contingent right to receive one share of Arcellx common stock under the merger terms.
Arcellx, Inc. chief medical officer Christopher Heery reported multiple equity changes tied to the completed tender offer and merger with Gilead Sciences. He tendered 23,749 shares of common stock, which were exchanged for $115.00 in cash per share plus a contractual contingent value right for an additional $5.00 in cash, subject to conditions.
Under the merger agreement, his outstanding stock options and restricted stock units, including performance-based awards, were canceled and converted into cash payments based on the $115.00 closing amount per underlying share, plus one contingent value right for each underlying share. On the same date, he received a new grant of 45,138 performance-based restricted stock units, each representing a contingent right to receive one share of Arcellx common stock.